Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from January 9, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 9, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$56.50 – $59.00Entry zone — fair-value band

$60.15Published — price the day we called it

$67.37Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$37.44Window close — end-of-window price, context only

What happened

Partial

Reached 56% of the predicted growth at its peak, without hitting the target.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+6.7%

peak, from the publication price

Window close

$37.44

end-of-window price, context only

Days to target

—

Window

January 9, 2026 – April 9, 2026

The thesis — published January 9, 2026

Predicted growth

+12%

over the measurement window

Target price

$67.37

the price the thesis aimed for

Entry zone

$56.50 – $59.00

the fair-value band we waited for

Price at publication

$60.15

published January 9, 2026

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is getting a lot of attention now because its oral Wegovy pill is becoming easier to find nationwide, including support from Amazon Pharmacy. That could keep demand expectations high and keep investors focused on the stock. Short term it can swing higher quickly after big rollout headlines, so it's safer to wait for a drop before buying.

Primary drivers

More pharmacies and telehealth services make the drug easier to buy
Leader in GLP-1 drugs so it stays central to industry growth
Big news can push the price up then cause fast consolidation
Questions about execution and pricing can quickly change value

How it played out

NVO: target was not reached

Lyra published NVO at $60.15 on 2026-01-09 with expected growth of 12%. The thesis pointed to wider access for oral Wegovy, including pharmacies and telehealth services, Novo Nordisk's role in GLP-1 drugs, headline-driven swings, and risks around execution and pricing.

Inside the window, the stock rose to a peak of $64.16 on 2026-01-23, a 6.7% gain. That stayed below the $67.37 target. By 2026-04-09, it ended at $37.44. The thesis partially played out early, but the target was missed.

What happened during the window

On 2026-01-16, Investor's Business Daily reported that oral Wegovy had 3,071 prescriptions in its first week on the market. On 2026-03-24, the New York Post reported that the FDA had approved Wegovy HD, a 7.2 mg semaglutide dose.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals